The antimalarial drug has been controversial in part due to the support of US President Donald Trump, as well as the implications of the study published in the British medical journal The Lancet last month.
READ MORE: Medical journal questions results of study on hydroxychloroquine coronavirus
[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]
The study authors stated that Surgisphere, the company that provided the data, would not transfer the entire data set for independent review and that they “can no longer vouch for the veracity of the main sources of data”.
Surgisphere was not immediately available for comment.
The Lancet in a statement said “there are many outstanding questions about Surgisphere and the data that would have been included in this study. “
WHO stops clinical trials on hydroxychloroquine
See the link »